Last checked at 
NetScientific PLC - London-based life sciences and sustainability, technology investment and commercialisation firm - Says it arranged an investment of a further USD1 million into EpiBone Inc, Lifesciences' portfolio company.
States the investment consists of USD734,000 from NetScientific's balance sheet and USD266,000 in advised funds from the company's corporate finance and venture capital subsidiary EMV Capital Ltd. Explains funding will enable EpiBone to accelerate the development of its pipeline. Is planning to support EpiBone in building a presence in the UK and Europe post-investment.
"We see EpiBone as an emerging leader in the regenerative medicine space, which is now coming of age. Its platform technology has the potential to transform the bone and cartilage space by making implants from patients' own cells across multiple applications. This is another example of NetScientific's judicious investment approach to build stakes in businesses, and supporting its Trans-Atlantic model, as it accelerates the portfolio company growth to deliver superior investment returns," NetScientific Chief Executive Ilian Iliev.
Current stock price: 107.50 pence
Year-to-date change: up sharply from 46.50p
By Abby Amoakuh; abbyamoakuh@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
